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Summary p53 protein was detected by immunohistochemistry in 42% of 52 colorectal adenocarcinomas.
Positive tumours were significantly more frequent in the distal colon, and demonstrated a higher rate of cell
proliferation. No correlation was found with tumour grade, Dukes' stage, presence of DNA aneuploidy or
patient survival. The role of p53 in colorectal carcinogenesis is discussed with particular reference to
differences between proximal and distal large bowel cancers.
p53 is a 53kD nuclear protein, highly conserved in verte-
brates, which is believed to regulate entry into and progres-
sion through the normal cell cycle (Mercer et al., 1984). Like
c-myc it is induced during transition from Go to G, phase
(Milner & Milner, 1981; Reich & Levine, 1984), and is
present at low levels in most normal fetal and adult tissues
(Rogel et al., 1985). Studies of p53 expression in cultured
cells suggest that increased levels are associated either with
an abnormal mutated protein (Finlay et al., 1988), or stab-
lisation of the protein in a complex with viral antigens, e.g.
SV40 large T antigen (Lane & Crawford, 1979). Point muta-
tions occurring in a highly conserved region of the gene are
known to activate p53 in the primary rat embryo fibroblast
transfection assay for dominant oncogenes (Hinds et al.,
1989), whereas the wild type protein has a tumour suppressor
action (Finlay et al., 1989). The presence of increased levels
of protein may therefore provide a marker for mutated p53.
Elevated p53 expression has been described in a number of
human tumours including carcinoma of the breast (Crawford
et al., 1984; Cattoretti et al., 1988; Thompson et al., 1990),
colorectum (Crawford et al., 1984), and lung (Iggo et al.,
1990). Colorectal cancer is characterised by frequent deletion
of chromosome 17p close to the p53 locus (Vogelstein et al.,
1988), and elevated protein levels have been found by radio-
immunoassay in 44% of tumours (Crawford et al., 1984).
These studies suggest that in some tumours hemizygous dele-
tion of one p53 allele is accompanied by mutation and
overexpression of the other. Recently van den Berg et al.
(1989) described the immunohistochemical detection of p53
in 55% of 29 colorectal cancers. However no information
was given regarding the relationship of p53 expression to
clinico-pathological variables several of which are believed to
correlate with the biological aggressiveness and stage of pro-
gression of a tumour. The aim of the present study was to
assess these relationships in a larger series and investigate the
value of the immunocytochemical detection of p53 as a prog-
nostic indicator.
Materials and methods
Fresh tumour tissue was obtained from 52 adenocarcinomas
of the large bowel from 52 patients. A single 4 p frozen
section was cut from each tumour, air dried overnight, and
fixed for 15 min in acetone at 4'C.
In five cases tissue was available from up to five different
areas of the same tumour. These were included in the main
series in order to assess the effect of intra-tumour hetero-
geneity on the detection of p53.
Sections were incubated with Pab421, a monoclonal anti-
body to murine and human p53, at a dilution of 1:200 of
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ascites fluid for 30 min. Sections were washed in Tris buffered
saline and incubated successively with biotinylated rabbit
anti-mouse immunoglobulin for 10 min, streptavidin-peroxi-
dase for 5 min, and amino-ethylcarbazole for 10 min (Zymed
Laboratories Inc). Staining was controlled by omission of the
primary antibody.
Follow-up was available for 41 out of 52 cases (mean
follow-up = 35.4 months; range 1-84 months). Median age
was 69 years and 52% of the series was male. Twenty-two
tumours were located in the rectum; 11 in the sigmoid colon;
three in the descending colon; two in the transverse colon;
two in the ascending colon, and 12 in the caecum. For
further analysis these were divided into left sided (rectum,
sigmoid and descending colon) and right sided lesions. All
cancers were staged at the time of resection, and reviewed by
one of us (NS) for histological grade, type of margin
(infiltraing vs expanding) and presence of a host lymphocyte
response at the tumour edge.
Ploidy was determined by flow cytometry using an estab-
lished technique previously described (Quirke et al., 1987).
Proliferation was assessed in 24 diploid tumours using the
Para 1 cell cycle analysis program (Bagwell, 1979) and ex-
pressed as the proliferative index (PI) which is the sum of
%S and %G2M phases. Median CV was 5.8%.
Statistics
Frequency of p53 positive tumours was compared for each
variable using Chi square analysis with Yates correction.
Proliferation was also compared in p53 positive and negative
tumours using Students t test. Kaplan-Meier survival curves
were constructed using the BMDP 1L statistics package and
assessed using the Log rank test.
Results
p53 was detected immunohistochemically in 22 out of 52
(42%) adenocarcinomas. Staining was confined to malignant
nuclei (Figure 1) and was never found in adjacent 'normal'
mucosa. Although some variation was noted in the propor-
tion of nuclei which contained pS3, 70% of nuclei or more
were stained in all positive cases. No variation was found
between different areas of the same tumour in the five cases
which were assessed for intra-tumour heterogeneity (Table I).
The relationship between p53 expression and several clini-
co-pathological variables is summarised in Table II. No cor-
relation was found with tumour grade, Dukes' stage, invasive
margin, presence of a host lymphocyte response or tumour
ploidy. A trend was seen towards a higher rate of cell pro-
liferation in p53 positive diploid tumours (x = 27.3% cf
20.9%) which just reached statistical significance (P<0.05)
using Students t test. Interestingly left sided cancers ex-
pressed p53 more often than right sided lesions (P<0.05).
Patient survival was predicted by Dukes' stage (P = 0.04);
presence of a host lymphocyte response (P = 0.04), and
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Figure 1 Colorectal carcinoma: a, malignant nuclei are stained
for p53 protein ( x 400), b, control.
nature of the invasive margin (P = 0.001). Tumour grade and
ploidy were not statistically significant indicators of prog-
nosis in this series. No difference in survival was found
between p53 positive and negative tumours: median survival
48.1 and 49.2 months respectively (Figure 2).
Table I p53 expression in different areas of the same tumour
Tumour Number ofareas examined p53
1 2 2/2
2 4 4/4
3 2 2/2
4 5 0/5
5 2 0/2
Table II p53 expression and clinico-pathological variables
Number p53 (%)
Clinico-pathological variable ofcases positive
Sex: male 27 54.5% NS
female 25 33.3%
Age: <69 26 35% NS
>69 26 45%
Tumour site: left colon 36 52.8% P<0.05
right colon 16 18.8%
Tumour grade: poorly differentiated 13 46.1% NS
other 39 41%
Dukes' stage: A 2 0%
B 28 39.3% NS
C 22 50%
Tumour margin: infiltrating 12 50% NS
expanding 40 40%
Lymphocyte response: present 8 37.5% NS
absent 44 43.2%
Tumour ploidy: DNA diploid 24 46.2% NS
DNA aneuploid 28 50%
Time (months)
Figure 2 Survival in p53 positive and negative tumours.
Discussion
Oncogenes and tumour suppressor genes are believed to play
a fundamental role in the initiation and progression of most
neoplasms. Several of these genes are implicated in colorectal
cancer. K-ras mutations and altered c-myc expression have
been described in 47% (Vogelstein et al., 1988) and 72%
(Erisman et al., 1985) of colonic cancers respectively, while
the FPC locus on chromosome 5q, a putative tumour sup-
pressor gene, is deleted in up to 35% of sporadic carcinomas
(Vogelstein et al., 1988). More recently alterations in p53
expression have been described in between 44% (Crawford et
al., 1984) and 55% (van den Berg et al., 1989) of large bowel
tumours. Baker et al. (1989) has demonstrated mutation of
the p53 gene in two tumours associated with increased
mRNA production. Remvikos et al. (1990) found a signifi-
cant association between elevated p53 and the presence of
DNA aneuploidy but not Dukes' stage. They did not how-
ever investigate cell proliferation or prognosis. With the
exception of the latter study, which investigated 41 tumours,
no information is available on the relationship ofp53 expres-
sion to other clinic-pathological variables in colorectal car-
cinoma, including patient survival.
We have confirmed the expression of elevated levels ofp53
in 42% of tumours. No correlation was found with a number
of pathological variables with the exception of cell prolifera-
tion in diploid tumours, and tumour site. The latter is parti-
cularly interesting as other studies support the biological
distinction of left and right sided large bowel cancer. c-myc
expression (Rothberg et al., 1985), 17p and 18q chromosome
deletions (Kern et al., 1989; Delattre et al., 1989) are all
commoner in left sided lesions. The demographic features of
proximal tumours are known to differ from more distal ones
(Moller-Jensen, 1984), and the incidence of caecal cancer is
increasing whilst that of rectal cancer is in decline (Beart et
al., 1983). It is reasonable to suggest therefore that aetiologic
factors and the molecular basis of neoplastic transformation
differ around the colorectum.
The relationship of p53 expression to cell proliferation in
diploid tumours is perhaps not surprising given the role of
p53 in normal cells where it appears to regulate entry into
the cell cycle. Constitutive expression of muated p53 might
conceivable prevent dividing cells from becoming quiescent.
The lack of correlation with established prognostic
indicators such as tumour grade, Dukes' stage, type of mar-
gin, and tumour ploidy is consistent with the failure of p53
expression to predict survival. This contrasts with breast
cancer where in two independent studies p53 expression has
been related to oestrogen receptor status, a known prognostic
indicator (Cattoretti et al., 1988; Thompson et al., 1990).
Little information is available regarding the role of other
oncogenes in determining prognosis in large bowel cancer.
Kern et al. (1989) report that K-ras mutations and Sq dele-
tions do not predict survival whereas deletions of 17p and
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18q are significantly associated with distant metastasis and
reduced survival. These studies suggest that loss of tumour
suppressor function, as identified by chromosome deletion,
may be more important in determining prognosis than proto-
oncogene activation. Our observations would support this.
There is little doubt that alterations in p53 will be increas-
ingly recognised in a variety of tumour types. The frequency
of abnormal expression in colorectal adenocarcinoma, and its
distribution around the bowel, would suggest that p53 plays
an important role in colorectal carcinogenesis, and supports
the belief that proximal and distal tumours are biologically
distinct.
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